



Pfizer Pipeline

As of May 12, 2011


Disclaimer

- As some programs are still confidential, some candidates may not be identified in this list. In these materials, Pfizer discloses Mechanism of Action (MOA) information for candidates from Phase 3 through regulatory approval. With a view to expanding the transparency of our pipeline, Pfizer is including new indications or enhancements, which target unmet medical need or represent significant commercial opportunities. The information contained on these pages is correct as of May 12, 2011.
- Visit Pfizer.com/pipeline, Pfizer's online database where you can learn more about our portfolio of new medicines and find out more about our Research and Development efforts around the world.

Table of Contents

| | |
|--|-----------|
| Pfizer Pipeline Snapshot | 4 |
| Cardiovascular & Metabolic Diseases | 5 |
| Inflammation & Immunology | 6 |
| Neuroscience & Pain | 7 |
| Oncology | 9 |
| Vaccines | 10 |
| Other Areas of Focus | 11 |
| Projects Discontinued Since Last Update | 13 |

Pfizer Pipeline Snapshot



Pipeline represents progress of R&D programs since 2/28/11
Included are 90 NMEs plus 24 additional indications



Pipeline represents progress of R&D programs since 9/27/10
Included are 93 NMEs plus 25 additional indications



Pfizer Pipeline – May 12, 2011

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|-----------------------------|--|--|--------------|
| Cardiovascular and Metabolic Diseases | Eliquis (formerly apixaban) | Factor Xa Inhibitor | Venous Thromboembolism Prevention (E.U.) | Registration |
| | Viviant | Selective Estrogen Receptor Modulator | Osteoporosis Treatment and Prevention | Registration |
| | Pristiq | Serotonin Norepinephrine Reuptake Inhibitor | Vasomotor Symptoms of Menopause | Registration |
| | Eliquis (formerly apixaban) | Factor Xa Inhibitor | Atrial Fibrillation | Phase 3 |
| | Eliquis (formerly apixaban) | Factor Xa Inhibitor | Venous Thromboembolism Treatment | Phase 3 |
| | PF-04971729 | | Diabetes Mellitus-Type 2 | Phase 2 |
| | PF-00489791 | | Raynaud's Syndrome | Phase 2 |
| | PF-05230901 | | Cachexia (Biologic) | Phase 1 |
| | CVX 096 (PF-04856883) | | Diabetes Mellitus-Type 2 (Biologic) | Phase 1 |
| | OAP-189 (PF-05212389) | | Diabetes Mellitus-Type 2, Obesity (Biologic) | Phase 1 |
| | PF-03882845 | | Diabetic Nephropathy | Phase 1 |
| | PF-04620110 | | Diabetes Mellitus-Type 2 | Phase 1 |
| | PF-04937319 | | Diabetes Mellitus-Type 2 | Phase 1 |
| | PF-04991532 | | Diabetes Mellitus-Type 2 | Phase 1 |
| | ▶ PF-05231023 | | Diabetes Mellitus-Type 2 (Biologic) | Phase 1 |
| | PF-05175157 | | Diabetes Mellitus-Type 2 | Phase 1 |
| | PF-05190457 | | Diabetes Mellitus-Type 2 | Phase 1 |
| | RN316 (PF-04950615) | | Hypercholesterolemia (Biologic) | Phase 1 |
| | ▶ PF-04840082 | | Osteoporosis Treatment and Prevention (Biologic) | Phase 1 |



New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

Pfizer Pipeline – May 12, 2011 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|-----------------------------------|--------------------------|--|---|---------|
| Inflammation and Immunology | tofacitinib (CP-690550) | JAK Inhibitor | Rheumatoid Arthritis | Phase 3 |
| | tofacitinib (CP-690550) | JAK Inhibitor | Psoriasis (Oral) | Phase 3 |
| | PF-04171327 | | Rheumatoid Arthritis | Phase 2 |
| | fezakinumab (ILV-094) | | Rheumatoid Arthritis, *Psoriasis (Biologic) | Phase 2 |
| | SBI-087 (PF-05230895) | | Rheumatoid Arthritis, *Lupus (Biologic) | Phase 2 |
| | ozoralizumab (ATN-103) | | Rheumatoid Arthritis (Biologic) | Phase 2 |
| | ▶ PF-05285401 | | Ulcerative Colitis (Biologic) | Phase 2 |
| | ▶ anrukinzumab (IMA-638) | | Ulcerative Colitis (Biologic) | Phase 2 |
| | ▶ PF-00547659 | | Crohn's Disease (Biologic) | Phase 2 |
| | ▶ PF-04236921 | | Crohn's Disease, *Rheumatoid Arthritis, *Lupus (Biologic) | Phase 2 |
| | ▶ PF-04136309 | | Liver Fibrosis | Phase 2 |
| | tofacitinib (CP-690550) | | Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis (Topical), Crohn's Disease, Ulcerative Colitis | Phase 2 |
| | SD-6010 | | Osteoarthritis | Phase 2 |
| | PF-04308515 | | Anti-Inflammatory | Phase 1 |
| | ILV-095 (PF-05212368) | | Psoriasis (Biologic) | Phase 1 |
| | ATR-107 (PF-05230900) | | Crohn's Disease (Biologic) | Phase 1 |
| | PF-05230905 (ATN-192) | | Rheumatoid Arthritis (Biologic) | Phase 1 |
| PF-04634817 | | Liver Fibrosis | Phase 1 | |

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – May 12, 2011 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---------------------------|--|--|--|--------------|
| Neuroscience & Pain | Tafamidis meglumine | Transthyretin (TTR) Dissociation Inhibitor | Transthyretin familial amyloid polyneuropathy (E.U.) | Registration |
| | Celebrex | COX-2 | Chronic Pain | Registration |
| | ▶ Immediate release oxycodone with Aversion® technology (formerly acurox) (King) | Mu-type opioid receptor (MOR-1) Agonist | Moderate to Severe Pain | Registration |
| | ▶ Immediate release oxycodone with Aversion® technology (with niacin) (formerly acurox) (King) | Mu-type opioid receptor (MOR-1) Agonist | Moderate to Severe Pain | Registration |
| | ▶ Remoxy (King) | Mu-type opioid receptor (MOR-1) Agonist | Moderate to Severe Pain | Registration |
| | ▶ ALO-02 Oxycodone-naltrexone core (King) | Mu-type opioid receptor (MOR-1) Agonist | Moderate to Severe Pain | Phase 3 |
| | bapineuzumab | Beta Amyloid Inhibitor | Alzheimer's Disease (Biologic) | Phase 3 |
| | latrepirdine (Dimebon) | MpTp Modulator | Alzheimer's Disease | Phase 3 |
| | Lyrica | Alpha-2 Delta Ligand | Epilepsy Monotherapy | Phase 3 |
| | Lyrica | Alpha-2 Delta Ligand | Central Neuropathic Pain due to Spinal Chord Injury | Phase 3 |
| | Lyrica | Alpha-2 Delta Ligand | Peripheral Neuropathic Pain (U.S.) | Phase 3 |
| | tanezumab | Nerve Growth Factor Inhibitor | OA Signs and Symptoms (Biologic) (On Clinical Hold) | Phase 3 |
| Lyrica | Alpha-2 Delta Ligand | QD (once a day dosing) | Phase 3 | |

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Pfizer Pipeline – May 12, 2011 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|---|---------------------------|--|--------------------------------|---------|
| Neuroscience & Pain (cont'd) | PF-02545920 | | Schizophrenia | Phase 2 |
| | PF-04494700 | | Alzheimer's Disease | Phase 2 |
| | CP-601,927 | | Depression | Phase 2 |
| | PF-04360365 (ponezumab) | | Alzheimer's Disease (Biologic) | Phase 2 |
| | ► Eladur (King) | | Chronic Pain | Phase 2 |
| | PF-03049423 | | Stroke Recovery | Phase 2 |
| | tanezumab | | Cancer Pain (Biologic) | Phase 2 |
| | PF-05236812 (AAB-003) | | Alzheimer's Disease (Biologic) | Phase 1 |
| | PF-04958242 | | Schizophrenia | Phase 1 |
| | Vabicaserin (PF-05208769) | | Schizophrenia | Phase 1 |
| | PF-05212377 (SAM-760) | | Alzheimer's Disease | Phase 1 |
| | PF-04427429 | | Migraine (Biologic) | Phase 1 |
| | PF-05089771 | | Chronic Pain | Phase 1 |
| | PF-04531083 | | Severe Chronic Pain | Phase 1 |
| PF-04995274 | | Alzheimer's Disease | Phase 1 | |

New Molecular Entity

New Indication or
Enhancement

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Pfizer Pipeline – May 12, 2011 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|------------------|---------------------------------|--|--|-------------------|
| Oncology | Sutent | Multiple Tyrosine Kinase Inhibitor | Unresectable Pancreatic Neuroendocrine Tumor | Registration (US) |
| | axitinib | VEGF Tyrosine Kinase Inhibitor | Renal Cell Carcinoma | Phase 3 |
| | PF-00299804 | pan-HER Inhibitor | Lung Cancer | Phase 3 |
| | bosutinib | Abl and src-family kinase inhibitor | Chronic Myelogenous Leukemia | Phase 3 |
| | neratinib | pan-HER Inhibitor | Breast Cancer | Phase 3 |
| | PF-02341066 (crizotinib) | c-MET-ALK Inhibitor | Lung Cancer, *Cancer | Phase 3 |
| | Sutent | Multiple Tyrosine Kinase Inhibitor | Renal Cell Carcinoma Adjuvant | Phase 3 |
| | Torisel | FKBP-Rapamycin Associated Protein | Renal Cell Carcinoma | Phase 3 |
| | inotuzumab ozogamicin (CMC-544) | | Aggressive Non-Hodgkin's Lymphoma (Biologic) | Phase 3 |
| | inotuzumab ozogamicin (CMC-544) | | Indolent Non-Hodgkin's Lymphoma (Biologic) | Phase 2 |
| | axitinib | | Lung Cancer, Thyroid Cancer | Phase 2 |
| | PF-00299804 | | Cancer | Phase 2 |
| | PD-0332991 | | Cancer | Phase 2 |
| | PF-01367338 | | Cancer | Phase 2 |
| | CVX 060 (PF-04856884) | | Cancer (Biologic) | Phase 1 |
| | CVX 241 (PF-05057459) | | Cancer (Biologic) | Phase 1 |
| | PF-03084014 | | Cancer | Phase 1 |
| | PF-03446962 | | Cancer (Biologic) | Phase 1 |
| | PF-05212384 (PKI-587) | | Cancer | Phase 1 |

New Molecular Entity

New Indication or Enhancement

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – May 12, 2011 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|------------------------------|---|--|---|--------------|
| Oncology (cont'd) | PF-03758309 | | Cancer | Phase 1 |
| | PF-04554878 | | Cancer | Phase 1 |
| | PF-04605412 | | Cancer (Biologic) | Phase 1 |
| | PF-04691502 | | Cancer | Phase 1 |
| | PF-04449913 | | Cancer | Phase 1 |
| Vaccines | Prevenar/Prevnar 13 Adult | Prophylactic Vaccine | Pneumococcal Disease | Registration |
| | ACC-001 (PF-05236806) | | Alzheimer's Disease | Phase 2 |
| | MnB rLP2086 (PF-05212366) | | Adolescent Meningitis, *Infant Meningitis | Phase 2 |
| | 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) (PF-05230894) | | Staph Aureus | Phase 1 |

New Molecular Entity

New Indication or Enhancement

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com

* Note: Additional indications in Phase 1



Pfizer Pipeline – May 12, 2011 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|----------------------------|--|--|---|--------------|
| Other Areas of Focus | Taliglucerase alfa | Enzyme Replacement Therapy | Gaucher Disease (Biologic) | Registration |
| | Macugen | Extracellular VEGF Antagonist | Diabetic Macular Edema (Biologic) (E.U.) | Registration |
| | Xiapex (E.U.) | Clostridial Collagenase for Injection | Peyronie's Disease (Biologic) (E.U.) | Phase 3 |
| | Eraxis/Vfend | Beta-D Glucan Synthase Inhibitor, Cyp P450 Mediated Alpha-lanosterol Demethylation | Aspergillosis | Phase 3 |
| | Zithromax/chloroquine | 5-OS Ribosome Inhibitor | Malaria | Phase 3 |
| | Moxidectin | Glutamate-gated chloride channel binding | Onchocerciasis (River Blindness) | Phase 3 |
| | bazedoxifene-conjugated estrogens (Aprela) | Tissue Selective Estrogen Complex | Menopausal Vasomotor Symptoms | Phase 3 |
| | tofacitinib (CP-690550) | | Transplant Rejection, Dry Eye | Phase 2 |
| | bosutinib | | Autosomal Dominant Polycystic Kidney Disease | Phase 2 |
| | PF-00868554 (filibuvir) | | Hepatitis C Virus | Phase 2 |
| | PF-04523655 | | Diabetic Macular Edema, Age-Related Macular Degeneration (Biologic) | Phase 2 |
| | PF-04217329 (taprenepag isopropyl) | | Glaucoma | Phase 2 |
| | Terguride | | Pulmonary Arterial Hypertension | Phase 2 |
| | PH-797804 | | Chronic Obstructive Pulmonary Disease | Phase 2 |
| | PF-00610355 | | Chronic Obstructive Pulmonary Disease | Phase 2 |
| | ▶ PF-00489791 | | Chronic Renal Failure | Phase 2 |
| | RN6G (PF-04382923) | | Age-Related Macular Degeneration (Biologic) | Phase 1 |
| | PNU-100480 | | Tuberculosis | Phase 1 |
| | PF-03715455 | | Chronic Obstructive Pulmonary Disease | Phase 1 |

New Molecular Entity

New Indication or Enhancement

▶ Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Pfizer Pipeline – May 12, 2011 (cont'd)

| Therapeutic Area | Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|--|------------------------------|--|--------------------------|---------|
| Other Areas of Focus (cont'd) | PF-04764793 (PF-00241939) | | Asthma | Phase 1 |
| | BMP-655 (PF-05208762) | | Tendon Repair (Biologic) | Phase 1 |

New Molecular Entity

New Indication or
Enhancement

► Indicates that the project is either new or has progressed in phase since the previous portfolio update of Pfizer.com



Projects Discontinued from Development since February 28, 2011

| Compound Name | Mechanism of Action (Phase 3 through regulatory approval) | Indication | Phase |
|--------------------------|--|---------------------------------------|---------|
| Iatrepirdine (Dimebon) | MpTp Modulator | Huntington's Disease | Phase 3 |
| Revatio IV | | Cardiac Surgery | Phase 2 |
| PH-797804 | | Pain | Phase 2 |
| PF-04191834 | | Pain | Phase 2 |
| SAM-531 (PF-05212365) | | Alzheimer's Disease, *Schizophrenia | Phase 2 |
| PF-03635659 | | Chronic Obstructive Pulmonary Disease | Phase 2 |
| CP-675206 (tremelimumab) | | Melanoma, *Pancreatic (Biologic) | Phase 2 |
| PF-00562271 | | Cancer | Phase 1 |
| PF-03893787 | | Asthma | Phase 1 |
| PF-04967544 | | Chronic Renal Failure | Phase 1 |
| PF-05212372 (PLA-950) | | Asthma | Phase 1 |
| PF-03526299 | | Asthma | Phase 1 |
| UK-396082 | | Pulmonary Fibrosis | Phase 1 |
| PF-04634817 | | Diabetic Nephropathy | Phase 1 |

New Molecular Entity

New Indication or Enhancement

* Note: Additional indications in Phase 1

